Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFLOAT: PFOB Partial Liquid Ventilation in Neonates with Severe BPD
NCT03041740Phase 1Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perflubron in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Children's Hospital of Philadelphia. Primary endpoints: Sustained oxygen desaturations at 10 days, Persistent hypotension at 10 days and 3 more. Started Jun 2017; status: completed.
02
Drugs
perflubron
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03041740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041740.